TRAW · Traws Pharma, Inc. · Share Buybacks
$0.37
+0.02 (+7.30%)
At close · Oct 27
Return incl. dividend (before tax)
Q2 2025 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.21M
Shares
15.37M
Volume · Oct 27
150.58K
Avg daily vol (3M)
568.6K
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-03-10 | — | $50,000,000 | — | — | 10-Q , filed 2026-08-14 |